Forward Pharma A/S operates as a biopharmaceutical company. The company engages in developing FP187, a proprietary formulation of dimethyl fumarate, which has been completed Phase II clinical trials used for the treatment of various inflammatory and neurological indications, including multiple sclerosis and other immune disorders, such as psoriasis. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.
http://www.priceseries.com/trade/FWP-Forward-Pharma-AS-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2020050820200513.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments